Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00628589 · ClinicalTrials.gov registry record · Phase 3
Staccato Loxapine in Agitated Patients With Schizophrenia
A Phase 3 study, sponsored by Alexza Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 344
- Enrollment target
NCT00628589: Completed Phase 3 study, sponsored by Alexza Pharmaceuticals.
NCT00628589 is a Phase 3 study that has completed, run by Alexza Pharmaceuticals. The registered enrollment target is 344 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00628589, a Phase 3 study, has completed, sponsored by Alexza Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 344 participants
- Enrollment target
Study Summary
Phase 3 safety and efficacy study of Staccato Loxapine in the treatment of acute agitation in schizophrenic patients
Primary Outcome
The Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) comprises 5 items associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (min) to 7 (max). The PANSS-EC, the sum of these 5 subscales, thus ranges from 5 to 35. Individuals were eligible if they had a PANSS-EC of ≥14 (out of 35) and a score ≥4 (out of 7) on at least 1 of the 5 items.
Interventions
- DRUG Inhaled placebo
- DRUG Inhaled loxapine 5 mg
- DRUG Inhaled loxapine 10 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 344 participants |
| Start Date | 2008-02 |
| Est. Completion | 2008-05 |
| Phase | Phase 3 |
What the finished NCT00628589 record still lists
NCT00628589 is an interventional study that assigns participants to a tested intervention. The registered 344 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 3 interventions - of which Inhaled placebo is the first listed.
NCT00628589 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00628589 about?
NCT00628589 is a clinical study titled "Staccato Loxapine in Agitated Patients With Schizophrenia". Phase 3 safety and efficacy study of Staccato Loxapine in the treatment of acute agitation in schizophrenic patients
What is the current status of trial NCT00628589?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 344 participants. The study started on 2008-02. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00628589?
The interventions under investigation include: Inhaled placebo (DRUG), Inhaled loxapine 5 mg (DRUG), Inhaled loxapine 10 mg (DRUG).
Who is sponsoring clinical trial NCT00628589?
This trial is sponsored by Alexza Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00628589's enrollment target sits among peer trials
344 1050th of 2000 higher than 950 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06733363 · 344 participants · Phase 2
A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer
- NCT07179380 · 344 participants · Phase 3
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- NCT07304024 · 344 participants · Phase 1
A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound
- NCT03972657 · 345 participants · Phase 1
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia